Navigator Medicines Announces First Participants Dosed in a Phase Ib Trial of NAV-240, a Potential Best-in-Class Anti-OX40L, and Anti-TNFα Bispecific Antibody Therapeutic for Autoimmune Diseases

Navigator Medicines, Inc. announced that it dosed the first subjects in a Phase Ib multiple-ascending dose study in healthy volunteers, evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of NAV-240 after repeated administration.